At this point of the evolving RWD landscape, we thought it appropriate to begin to broadly assess the use of real world data.
Our survey is open now.
While the impact and legacy of the very much on-going pandemic most acutely hits those infected, their families and friends, and the frontline healthcare providers, one clear legacy of this extraordinary moment will be how it helped show real world data is a critical component of the life sciences industry’s future.
There is now a daily public consumption of complex, evolving real world health data to an extraordinary degree. From the original goal of “flattening the curve” to rolling averages, and rates for testing, cases, hospitalizations, deaths, vaccinations and more, data inserts itself into the daily discourse up, down, and across society. At the same time, real world data continues to increasingly impact virtually every facet of what the life sciences industry does - from R&D strategy to commercialization – across therapeutic areas.
Again, your support of our survey is appreciated.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.